Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Risedronate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

NCT00221299
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate, Parathyroid Hormone
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Effect of Actonel on Periodontal Health of Postmenopausal Women

NCT00594334
View directory record Official record
Conditions
Periodontal Disease
Interventions
Risedronate
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
40 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Not applicable Interventional

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

NCT00118508
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD

NCT00577837
View directory record Official record
Conditions
Postmenopausal
Interventions
risedronate, experimental
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
4
States / cities
Daytona Beach, Florida • Gainesville, Florida • Shawnee Mission, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

NCT00717145
View directory record Official record
Conditions
Postmenopausal, Non-lactating, Surgically Sterile
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use

NCT01875458
View directory record Official record
Conditions
Osteoporosis, With or Without Treatment, Bisphosphonate Treatment, Atypical Femur Fracture, Bisphosphonate Related Osteonecrosis of the Jaws (BRONJ), Healthy Volunteers
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

A Study of Monthly Risedronate for Osteoporosis

NCT00247273
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
7
States / cities
Lakewood, Colorado • Gainesville, Georgia • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

NCT00619957
View directory record Official record
Conditions
Other Osteoporosis
Interventions
Placebo tablet, Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
30 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Stuart, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

NCT03861091
View directory record Official record
Conditions
Lung Neoplasm
Interventions
risedronate, Matching placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
High Point, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 19, 2026, 5:12 AM EDT
Terminated Phase 4 Interventional

Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation

NCT00790101
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 4 Interventional

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose

NCT00577850
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
risedronate, alendronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Gainesville, Florida • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Back Pain, Spinal Fracture
Interventions
teriparatide, risedronate, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Montgomery, Alabama • Peoria, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

NCT00846196
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed No phase listed Observational

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

NCT00778154
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 1 Interventional

Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate

NCT00755872
View directory record Official record
Conditions
Bioavailability
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Fort Myers, Florida • Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Bone Loss in Women With Anorexia Nervosa

NCT00089843
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Testosterone, Actonel (risedronate), Placebo Actonel (risedronate), Placebo testosterone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

NCT00868907
View directory record Official record
Conditions
Healthy
Interventions
35 mg risedronate DR tablet
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 19, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

NCT00485953
View directory record Official record
Conditions
Bone Loss, Osteoporosis, Breast Cancer
Interventions
risedronate
Drug
Lead sponsor
Susan L. Greenspan
Other
Eligibility
55 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2017 · Synced Sep 19, 2026, 5:12 AM EDT